NGN Capital Company Profile

Background

NGN Capital is a venture capital firm established in 2003, specializing in healthcare investments across the United States and Europe. The firm focuses on ventures with the potential to achieve above-average private equity returns, emphasizing later-stage investments. NGN Capital's portfolio spans various segments within the healthcare and biotechnology sectors, including pharmaceuticals, medical devices, diagnostics, and healthcare services. The firm operates offices in New York, USA, and Heidelberg, Germany.

Key Strategic Focus

NGN Capital's strategic focus encompasses:

Investment Flexibility: Engaging in a broad spectrum of healthcare and biotechnology segments, such as drug products, medical devices, diagnostics, and healthcare services.

Stage Diversification: Investing across different stages, from selected early-stage opportunities to predominantly later-stage ventures.

Geographical Diversification: Concentrating investments primarily in the United States and Europe to leverage diverse market dynamics.

Financials and Funding

NGN Capital manages assets under management (AUM) totaling approximately $125 million across two funds. The firm has made 57 investments, with 30 successful exits. Notable investments include:

Cardiovalve: Participated in a later-stage venture capital round in August 2020.

OptiScan Biomedical Corporation: Led a $36 million Series B financing, focusing on continuous blood glucose monitoring systems.

Exosome Diagnostics: Engaged in multiple funding rounds, including a Series C in July 2017.

Pipeline Development

NGN Capital's portfolio includes companies at various stages of development:

Artisan Pharma: Focused on developing ART-123, a recombinant human thrombomodulin for treating disseminated intravascular coagulation in sepsis and deep vein thrombosis. Acquired by Asahi Kasei Pharma in November 2011.

Horizon Pharma: Specializes in treatments for arthritis, pain, and inflammation, with products like Duexa and Lodotra. Completed an initial public offering on NASDAQ in July 2011.

Javelin Pharmaceuticals: Developed Dyloject®, an injectable diclofenac formulation for pain management. Acquired by Hospira, Inc. in July 2010.

Technological Platform and Innovation

NGN Capital's portfolio companies leverage various proprietary technologies and scientific methodologies:

Micromet, Inc.: Developed BiTE® technology, a unique antibody-based format that harnesses T-cells' cytotoxic potential for treating cancer, inflammatory, and autoimmune diseases. Acquired by Amgen in March 2012.

OptiScan Biomedical Corporation: Focused on continuous blood glucose monitoring systems to support tight glycemic control in hospital patients.

Leadership Team

NGN Capital's leadership comprises experienced professionals with diverse backgrounds:

Kenneth S. Abramowitz: Co-Founder and Managing General Partner, with extensive experience in healthcare investments.

Peter Johann, Ph.D.: Managing General Partner, based in Heidelberg, Germany, bringing expertise in European healthcare markets.

John Costantino: Manager, contributing to the firm's strategic direction and investment decisions.

Alexander Cuomo: Chief Financial Officer, overseeing financial operations and fund management.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within NGN Capital's leadership team.

Competitor Profile

Market Insights and Dynamics

The healthcare venture capital market is characterized by:

Market Size and Growth: A substantial and growing market driven by advancements in medical technology, increasing healthcare needs, and a focus on innovative treatments.

Industry Trends: Emphasis on personalized medicine, biotechnology innovations, and digital health solutions.

Competitor Analysis

Key competitors in the healthcare venture capital space include:

NEA (New Enterprise Associates): A venture capital firm investing across multiple sectors, including healthcare and biotechnology.

Venrock: Focuses on early-stage investments in healthcare, technology, and energy sectors.

Canaan Partners: Invests in early to late-stage companies in technology and healthcare.

Strategic Collaborations and Partnerships

NGN Capital has engaged in significant collaborations to enhance its market position:

Artisan Pharma: Led a $39 million Series A financing, resulting in the development of ART-123 and subsequent acquisition by Asahi Kasei Pharma.

Santhera Pharmaceuticals: Led Series B and pre-IPO rounds, supporting the company's focus on neuromuscular diseases and successful public offering in November 2006.

Operational Insights

NGN Capital's strategic considerations include:

Diversified Investment Approach: Balancing investments across various healthcare segments and stages to mitigate risks and capitalize on growth opportunities.

Geographical Reach: Establishing a presence in both the U.S. and European markets to leverage regional strengths and opportunities.

Strategic Opportunities and Future Directions

NGN Capital aims to:

Expand Investment Portfolio: Continue identifying and investing in promising healthcare ventures with high growth potential.

Leverage Technological Innovations: Support companies developing cutting-edge technologies in biotechnology, medical devices, and healthcare services.